industry

Serum to double investment in Biocon's unit to $300 mn; aim to generate higher EBITDA going ahead: Kiran Mazumdar-Shaw


The Serum Institute of Life Sciences will double its investment in one of Biocon Ltd’s units, giving it access to 100 million doses of vaccines annually along with the distribution rights to Serum’s vaccine portfolio, the Indian biopharma firm said on Tuesday. “Serum will not have an operational involvement but have a board seat”, says Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited.



READ SOURCE

Readers Also Like:  India's pharma industry has far to go to account for 20% of manufacturing sector

This website uses cookies. By continuing to use this site, you accept our use of cookies.